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26I n 2009, Kidney Disease: Improving Global Outcomes(KDIGO) published the KDIGO Clinical Practice Guidelinefor the Diagnosis, Evaluation, Prevention, and Treatment of
Chronic Kidney Disease–Mineral and Bone Disorder (CKD-
MBD).1 At that time, the Work Group acknowledged the lack
of high-quality evidence on which to base recommendations.
Over the years that followed, multiple randomized controlled
trials (RCTs) and prospective cohort studies examined some
of the key issues underlying the assessment, development,
progression, and treatment of CKD-MBD. KDIGO recognizes
the need to reexamine the currency of its guidelines on
a periodic basis, and therefore convened a Controversies
Conference in 2013, titled “CKD-MBD: Back to the Future.”2
The conference participants concluded that most of the
2009 recommendations1 were still applicable in current
practice; however, a total of 12 recommendations were
identiﬁed for revision, based on new data. As a result, a Work
Group was convened to undertake a “selective update”3 of the
2009 KDIGO CKD-MBD Guideline (Table 1).1 Notably,
despite the availability of results from several new key clinical
trials, large gaps of knowledge still remained. Accordingly,
many of the “opinion-based” recommendation statements
from the 2009 Guideline1 remain unchanged (see summary of
KDIGO CKD-MBD recommendations).
Similar to the original 2009 KDIGO CKD-MBD Guide-
line,1 development of the 2017 Update3 followed a rigorous
process of evidence review and appraisal, based on systematic
reviews of results from clinical trials. The structured approach
was modeled after the GRADE system,4 which ascribes grades
to the quality of the overall evidence and strength for each
recommendation. Where appropriate, the Work Group issued
“not graded” recommendations, based on general advice, that
were not part of a systematic evidence review.
Despite the dearth of high-quality evidence identiﬁed in
several areas pertaining to CKD-MBD, the Work Group was
committed to developing a comprehensive guideline docu-
ment that is of highest value to the nephrology community.
The list of research recommendations in each chapter of theKidney International (2017) 92, 26–36
Table 1 | Comparison of the 2017 and 2009 KDIGO CKD-MBD Guideline recommendations
2017 revised KDIGO CKD-MBD
recommendations3 2009 KDIGO CKD-MBD recommendations1 Brief rationale for updating
3.2.1. In patients with CKD G3a–G5D with
evidence of CKD-MBD and/or risk factors for
osteoporosis, we suggest BMD testing to
assess fracture risk if results will impact
treatment decisions (2B).
3.2.2. In patients with CKD G3a–G5D with
evidence of CKD-MBD, we suggest that BMD
testing not be performed routinely, because
BMD does not predict fracture risk as it does in
the general population, and BMD does not
predict the type of renal osteodystrophy (2B).
Multiple new prospective studies have
documented that lower DXA BMD predicts
incident fractures inpatientswithCKDG3a–G5D.
The order of these ﬁrst 2 recommendations was
changed because a DXA BMD result might
impact the decision to perform a bone biopsy.
3.2.2. In patients with CKD G3a–G5D, it is
reasonable to perform a bone biopsy if
knowledge of the type of renal osteodystrophy
will impact treatment decisions (Not Graded).
3.2.1. In patients with CKD G3a–G5D, it is
reasonable to perform a bone biopsy in various
settings including, but not limited to:
unexplained fractures, persistent bone pain,
unexplained hypercalcemia, unexplained
hypophosphatemia, possible aluminum toxicity,
and prior to therapy with bisphosphonates in
patients with CKD-MBD (Not Graded).
The primary motivation for this revision was
the growing experience with osteoporosis
medications in patients with CKD, low BMD,
and a high risk of fracture. The inability to
perform a bone biopsy may not justify
withholding antiresorptive therapy from
patients at high risk of fracture.
4.1.1. In patients with CKD G3a–G5D,
treatments of CKD-MBD should be based on
serial assessments of phosphate, calcium, and
PTH levels, considered together (Not Graded).
This new recommendation was provided in
order to emphasize the complexity and
interaction of CKD-MBD laboratory parameters.
4.1.2. In patients with CKD G3a–G5D, we
suggest lowering elevated phosphate levels
toward the normal range (2C).
4.1.1. In patients with CKD G3a–G5D, we
suggest maintaining serum phosphate in the
normal range (2C). In patients with CKD G5D,
we suggest lowering elevated phosphate
levels toward the normal range (2C).
There is an absence of data supporting
that efforts to maintain phosphate in the
normal range are of beneﬁt to CKD G3a–G4
patients, including some safety concerns.
Treatment should be aimed at overt
hyperphosphatemia.
4.1.3. In adult patients with CKD G3a–G5D, we
suggest avoiding hypercalcemia (2C).
In children with CKD G3a–G5D, we suggest
maintaining serum calcium in the age-
appropriate normal range (2C).
4.1.2. In patients with CKD G3a–G5D, we
suggest maintaining serum calcium in the
normal range (2D).
Mild and asymptomatic hypocalcemia (e.g., in
the context of calcimimetic treatment) can be
tolerated in order to avoid inappropriate
calcium loading in adults.
4.1.4. In patients with CKD G5D, we suggest
using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and
3.0 mEq/l) (2C).
4.1.3. In patients with CKD G5D, we suggest
using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and 3.0
mEq/l) (2D).
Additional studies of better quality are
available; however, these do not allow for
discrimination of beneﬁts and harm between
calcium dialysate concentrations of 1.25 and
1.50 mmol/l (2.5 and 3.0 mEq/l). Hence, the
wording is unchanged, but the evidence grade
is upgraded from 2D to 2C.
4.1.5. In patients with CKD G3a–G5D, decisions
about phosphate-lowering treatment should
be based on progressively or persistently
elevated serum phosphate (Not Graded).
4.1.4. In patients with CKD G3a–G5 (2D) and G5D
(2B), we suggest using phosphate-binding
agents in the treatment of hyperphosphatemia.
It is reasonable that the choice of phosphate
binder takes into account CKD stage, presence of
other components of CKD-MBD, concomitant
therapies, and side effect proﬁle (Not Graded).
Emphasizes theperception thatearly “preventive”
phosphate-lowering treatment is currently not
supported by data (see Recommendation 4.1.2).
The broader term ”phosphate-lowering“
treatment is used instead of phosphate-binding
agents since all possible approaches (i.e., binders,
diet, dialysis) can be effective.
4.1.6. In adult patients with CKD G3a–G5D
receiving phosphate-lowering treatment, we
suggest restricting the dose of calcium-based
phosphate binders (2B).
In children with CKD G3a–G5D, it is reasonable
to base the choice of phosphate-lowering
treatment on serum calcium levels (Not
Graded).
4.1.5. In patients with CKD G3a–G5D and
hyperphosphatemia, we recommend restricting
the dose of calcium-based phosphate binders
and/or the dose of calcitriol or vitamin D analog
in the presence of persistent or recurrent
hypercalcemia (1B).
In patients with CKD G3a–G5D and
hyperphosphatemia, we suggest restricting the
dose of calcium-based phosphate binders in
the presence of arterial calciﬁcation (2C) and/or
adynamic bone disease (2C) and/or if serum
PTH levels are persistently low (2C).
New evidence from 3 RCTs supports a more
general recommendation to restrict calcium-
based phosphate binders in
hyperphosphatemic patients across all
severities of CKD.
(Continued on next page)
M Ketteler et al.: Summary of 2017 KDIGO CKD-MBD Guideline Update gu ide l i ne summary
Kidney International (2017) 92, 26–36 27
2017 revised KDIGO CKD-MBD
recommendations3 2009 KDIGO CKD-MBD recommendations1 Brief rationale for updating
4.1.8. In patients with CKD G3a–G5D, we
suggest limiting dietary phosphate intake in
the treatment of hyperphosphatemia alone or
in combination with other treatments (2D).
It is reasonable to consider phosphate source
(e.g., animal, vegetable, additives) in making
dietary recommendations (Not Graded).
4.1.7. In patients with CKD G3a–G5D, we
suggest limiting dietary phosphate intake in
the treatment of hyperphosphatemia alone or
in combination with other treatments (2D).
New data on phosphate sources were deemed
important to include as an additional qualiﬁer
to the previous recommendation.
4.2.1. In patients with CKD G3a–G5 not on
dialysis, the optimal PTH level is not known.
However, we suggest that patients with levels
of intact PTH progressively rising or
persistently above the upper normal limit for
the assay be evaluated for modiﬁable factors,
including hyperphosphatemia, hypocalcemia,
high phosphate intake, and vitamin D
deﬁciency (2C).
4.2.1. In patients with CKD G3a–G5 not on
dialysis, the optimal PTH level is not known.
However, we suggest that patients with
levels of intact PTH above the upper normal
limit of the assay are ﬁrst evaluated for
hyperphosphatemia, hypocalcemia, and
vitamin D deﬁciency (2C).
It is reasonable to correct these abnormalities
with any or all of the following: reducing
dietary phosphate intake and administering
phosphate binders, calcium supplements, and/
or native vitamin D (Not Graded).
The Work Group felt that modest increases in
PTH may represent an appropriate adaptive
response to declining kidney function and has
revised this statement to include “persistently”
above the upper normal PTH level as well as
“progressively rising” PTH levels, rather than
“above the upper normal limit.” That is,
treatment should not be based on a single
elevated value.
4.2.2. In adult patients with CKD G3a–G5 not
on dialysis, we suggest that calcitriol and
vitamin D analogs not be routinely used (2C).
It is reasonable to reserve the use of calcitriol
and vitamin D analogs for patients with CKD
G4–G5 with severe and progressive
hyperparathyroidism (Not Graded).
4.2.2. In patients with CKD G3a–G5 not on
dialysis, in whom serum PTH is progressively
rising and remains persistently above the upper
limit of normal for the assay despite correction
of modiﬁable factors, we suggest treatment
with calcitriol or vitamin D analogs (2C).
Recent RCTs of vitamin D analogs failed to
demonstrate improvements in clinically
relevant outcomes but demonstrated
increased risk of hypercalcemia.
In children, calcitriol and vitamin D analogs
may be considered to maintain serum calcium
levels in the age-appropriate normal range
(Not Graded).
4.2.4. In patients with CKD G5D requiring
PTH-lowering therapy, we suggest calcimimetics,
calcitriol, or vitamin D analogs, or a combination
of calcimimetics with calcitriol or vitamin D
analogs (2B).
4.2.4. In patients with CKD G5D and elevated or
rising PTH, we suggest calcitriol, or vitamin D
analogs, or calcimimetics, or a combination of
calcimimetics and calcitriol or vitamin D
analogs be used to lower PTH (2B).
 It is reasonable that the initial drug selection
for the treatment of elevated PTH be based
on serum calcium and phosphate levels and
other aspects of CKD-MBD (Not Graded).
 It is reasonable that calcium or non–
calcium-based phosphate binder dosage be
adjusted so that treatments to control PTH
do not compromise levels of phosphate and
calcium (Not Graded).
 We recommend that, in patients with hy-
percalcemia, calcitriol or another vitamin D
sterol be reduced or stopped (1B).
 We suggest that, in patients with hyper-
phosphatemia, calcitriol or another vitamin
D sterol be reduced or stopped (2D).
 We suggest that, in patients with hypocalce-
mia, calcimimetics be reduced or stopped
depending on severity, concomitant medica-
tions, and clinical signs and symptoms (2D).
 We suggest that, if the intact PTH levels fall
below 2 times the upper limit of normal for
the assay, calcitriol, vitamin D analogs, and/
or calcimimetics be reduced or stopped (2C).
This recommendation originally had not been
suggested for updating by the KDIGO
Controversies Conference in 2013. However,
due to a subsequent series of secondary and
post hoc publications of the EVOLVE trial, the
Work Group decided to reevaluate
Recommendation 4.2.4 as well. Although
EVOLVE did not meet its primary endpoint, the
majority of the Work Group members were
reluctant to exclude potential beneﬁts of
calcimimetics for G5D patients based on
subsequent prespeciﬁed analyses. The Work
Group, however, decided not to prioritize any
PTH-lowering treatment at this time because
calcimimetics, calcitriol, or vitamin D analogs
are all acceptable ﬁrst-line options in G5D
patients.
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recommendations3 2009 KDIGO CKD-MBD recommendations1 Brief rationale for updating
4.3.3. In patients with CKD G3a–G5D with
biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest
that treatment choices take into account the
magnitude and reversibility of the biochemical
abnormalities and the progression of CKD,
with consideration of a bone biopsy (2D).
4.3.3. In patients with CKD G3a–G3b with
biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest
that treatment choices take into account the
magnitude and reversibility of the biochemical
abnormalities and the progression of CKD,
with consideration of a bone biopsy (2D).
Recommendation 3.2.2 now addresses the
indications for a bone biopsy prior to
antiresorptive and other osteoporosis
therapies. Therefore, 2009 Recommendation
4.3.4 has been removed and 2017
Recommendation 4.3.3 is broadened from CKD
G3a–G3b to CKD G3a–G5D.
4.3.4. In patients with CKD G4–G5D having
biochemical abnormalities of CKD-MBD, and
low BMD and/or fragility fractures, we suggest
additional investigation with bone biopsy prior
to therapy with antiresorptive agents (2C).
5.5. In patients with G1T–G5T with risk factors
for osteoporosis, we suggest that BMD testing
be used to assess fracture risk if results will
alter therapy (2C).
5.5. In patients with an estimated glomerular
ﬁltration rate greater than approximately 30
ml/min/1.73 m2, we suggest measuring BMD in
the ﬁrst 3 months after kidney transplant if
they receive corticosteroids, or have risk
factors for osteoporosis as in the general
population (2D).
2009 Recommendations 5.5 and 5.7 were
combined to yield 2017 Recommendation 5.5.
5.7. In patients with CKD G4T–G5T, we suggest
that BMD testing not be performed routinely,
because BMD does not predict fracture risk as
it does in the general population and BMD
does not predict the type of kidney transplant
bone disease (2B).
5.6. In patients in the ﬁrst 12 months after
kidney transplant with an estimated
glomerular ﬁltration rate greater than
approximately 30 ml/min/1.73 m2 and low
BMD, we suggest that treatment with vitamin
D, calcitriol/alfacalcidol, and/or antiresorptive
agents be considered (2D).
 We suggest that treatment choices be
inﬂuenced by the presence of CKD-MBD, as
indicated by abnormal levels of calcium,
phosphate, PTH, alkaline phosphatases, and
25(OH)D (2C).
 It is reasonable to consider a bone biopsy to
guide treatment (Not Graded).
There are insufﬁcient data to guide treatment
after the ﬁrst 12 months.
5.6. In patients in the ﬁrst 12 months after
kidney transplant with an estimated
glomerular ﬁltration rate greater than
approximately 30 ml/min/1.73 m2 and low
BMD, we suggest that treatment with vitamin
D, calcitriol/alfacalcidol, or bisphosphonates be
considered (2D).
 We suggest that treatment choices be
inﬂuenced by the presence of CKD-MBD, as
indicated by abnormal levels of calcium,
phosphate, PTH, alkaline phosphatases, and
25(OH)D (2C).
 It is reasonable to consider a bone biopsy to
guide treatment, speciﬁcally before the use
of bisphosphonates due to the high inci-
dence of adynamic bone disease (Not
Graded).
There are insufﬁcient data to guide treatment
after the ﬁrst 12 months.
The second bullet point is revised, consistent
with the new bone biopsy recommendation
(i.e., 2017 Recommendation 3.2.2).
25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; CKD, chronic kidney disease; DXA, dual-energy X-ray absorptiometry; MBD, mineral bone disorder; PTH,
parathyroid hormone, RCT, randomized controlled trial.
Changes to the above summarized recommendations resulted in renumbering of several adjacent guideline statements. Speciﬁcally, 2009 Recommendation 4.1.6 now
becomes 2017 Recommendation 4.1.7; 2009 Recommendation 4.1.8 now becomes 2017 Recommendation 4.1.9; 2009 Recommendation 4.3.5 now becomes 2017 Recom-
mendation 4.3.4; and 2009 Recommendation 5.8 now becomes 2017 Recommendation 5.7.
Table 1 | (Continued)
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vestigations, which in turn will help advance the evidence
base in CKD-MBD.
CHAPTER 3.2: DIAGNOSIS OF CKD-MBD: BONE
Bone mineral density testing
At the time of publication of the 2009 KDIGO CKD-MBD
Guideline,1 the literature addressing the ability to estimateKidney International (2017) 92, 26–36fracture risk in CKD from bone mineral density (BMD)
measurements by dual-energy X-ray absorptiometry (DXA)
was limited to cross-sectional studies that compared BMD in
CKD patients with and without a prevalent fracture. These
results were variable across studies and across skeletal sites.
Due to the lack of evidence that DXA BMD predicted frac-
tures in CKD patients as it does in the general population,
and the inability of DXA to indicate the histological type of29
gu ide l i ne summary M Ketteler et al.: Summary of 2017 KDIGO CKD-MBD Guideline Updatebone disease, the 2009 Guideline1 recommended that BMD
testing not be performed routinely in patients with CKD G3a
to G5D and CKD-MBD.
The evidence-based review for the 2017 KDIGO CKD-
MBD Guideline Update3 identiﬁed 4 prospective cohort
studies in adults demonstrating that DXA BMD predicted
fractures across the spectrum from CKD G3a to G5D. These
studies represent a substantial advance since the original 2009
Guideline was published.1 Despite the fact that the studies
were conducted across a range of CKD severity, the ﬁnding
that hip BMD predicted fractures was consistent across
studies, and 2 studies demonstrated associations comparable
to those seen in the absence of CKD.
Based on these insights, the Work Group concluded that
DXA BMD assessment is reasonable if a low or declining
BMD will lead to additional interventions to reduce falls or
use osteoporosis medications.
Renal osteodystrophy
Renal osteodystrophy is deﬁned as abnormal bone histology
and is 1 component of the bone abnormalities of CKD-MBD.
Bone biopsy is the gold standard for the diagnosis and
classiﬁcation of renal osteodystrophy. The 2009 KDIGO CKD-
MBD Guideline1 noted that DXA BMD does not distinguish
among types of renal osteodystrophy. Further, it concluded
that the diagnostic utility of biochemical markers was limited
by their poor sensitivity and speciﬁcity. Differences in para-
thyroid hormone (PTH) assays have also contributed to con-
ﬂicting results across studies. For the 2017 Update,3 the Work
Group encouraged the continued use of PTH trends, rather
than 1-time values, to guide therapy. When PTH trends are
inconsistent, a bone biopsy is a reasonable consideration if the
results may lead to changes in therapy.
The 2009 Guideline1 recommended a bone biopsy prior to
antiresorptive therapy in patients with CKD G4 to G5D and
evidence of biochemical abnormalities of CKD-MBD, low
BMD, and/or fragility fractures. However, the Work Group is
well aware that clinical experience concerning performance
and evaluation of bone biopsies may be limited. There is
growing evidence that antiresorptive therapies are effective in
patients with CKD G3a to G3b and G4, and no robust evidence
that these medications induce adynamic bone disease. There-
fore, the 2017 Update3 no longer suggests performing a bone
biopsy prior to initiation of these medications.
CHAPTER 4.1: TREATMENT OF CKD-MBD TARGETED AT
LOWERING HIGH SERUM PHOSPHATE AND MAINTAINING
SERUM CALCIUM
Phosphate-lowering therapy
Assessment. The previous Recommendation 4.1.1 from
the 2009 KDIGO CKD-MBD Guideline1 provided guidance
regarding treatment based on serum phosphate levels in
different glomerular ﬁltration rate (GFR) categories of CKD.
The accumulated evidence did not lead to a substantially
different conclusion in that there is an increasing risk of all-
cause mortality with increasing levels of serum phosphate30in a consistent and direct fashion. For GFR decline and car-
diovascular event rate, results were less conclusive.
The Work Group considered it reasonable to take the
context of therapeutic interventions into account when
assessing values of phosphate, calcium, and PTH. Further, it is
important to emphasize the interdependency of these
biochemical parameters. Based on these assumptions, the
Work Group also decided to split the previous 2009 Recom-
mendation 4.1.1 into 2 new Recommendations: 4.1.1 (diag-
nostic recommendation based on accumulated observational
evidence) and 4.1.2 (therapeutic recommendation based
mostly on RCTs).
Treatment of hyperphosphatemia. Following the publica-
tion of the 2009 KDIGO CKD-MBD Guideline,1 additional
high-quality evidence now links higher concentrations of
phosphate with mortality among patients with CKD G3a to
G5 or after transplantation. However, there is still a lack of
trial data demonstrating that therapeutic approaches to lower
serum phosphate will improve patient-centered outcomes.
The 2009 Guideline1 suggested maintaining serum phos-
phate in the normal range for patients with CKD G3a to G3b
and G4. On reevaluating the evidence for the 2017 Update,3
the Work Group drew several conclusions: (i) the associa-
tion between serum phosphate and clinical outcome is not
monotonic; (ii) evidence is lacking to demonstrate the efﬁ-
cacy of phosphate binders for lowering serum phosphate in
patients with CKD G3a to G4; (iii) the safety of phosphate
binders in this population is unproven; and (iv) there is an
absence of data showing that dietary phosphate restriction
improves clinical outcomes.
Consequently, the Work Group has abandoned the pre-
vious suggestion to maintain phosphate in the normal range,
instead suggesting that treatment be focused on patients
with hyperphosphatemia. The Work Group recognizes that
preventing, rather than treating, hyperphosphatemia may be
of value in patients with CKD G3a to G5D, but acknowl-
edges that current data are inadequate to support the safety
or efﬁcacy of such an approach.
Phosphate-lowering therapies. The 2009 KDIGO CKD-
MBD Guideline1 stated that available phosphate binders are
all effective in the treatment of hyperphosphatemia, and there
is evidence that calcium-free binders may favor halting the
progression of vascular calciﬁcation compared with calcium-
containing binders. Concerns about calcium balance and
uncertainties about phosphate lowering in CKD patients not
on dialysis, coupled with additional hard–endpoint RCTs and
a systematic review, prompted the 2017 Update Work Group
to reevaluate this recommendation. Based on the current ev-
idence, the Work Group concluded that normophosphatemia
may not be an indication to start phosphate-lowering treat-
ments. Further, not all phosphate binders are interchangeable.
Particularly in the case of CKD patients not on dialysis, the
2017 Update Work Group clariﬁed that phosphate-lowering
therapies may only be indicated in the event of “progressive
or persistent hyperphosphatemia,” and not to prevent
hyperphosphatemia. When thinking about risk-beneﬁt ratios,Kidney International (2017) 92, 26–36
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(e.g., due to side effects such as gastrointestinal distress and
binding of essential nutrients). The Work Group also adopted
the term “phosphate-lowering treatment” instead of “phos-
phate-binding agents,” because all possible approaches
(i.e., binders, diet, and dialysis) can be effective.
New evidence suggested a need to revise the 2009
recommendation regarding the use of calcium-based phos-
phate binders. These recent RCTs added hard–end point data
to the comparison of calcium-containing and calcium-free
phosphate binders. Overall, the Work Group concluded that
excess exposure to calcium through diet, medications, or
dialysate may be harmful across all GFR categories of CKD,
regardless of whether other candidate markers of risk (such as
hypercalcemia, arterial calciﬁcation, adynamic bone disease,
or low PTH levels) are also present. Therefore, the Work
Group deleted these previous qualiﬁers in the 2009 recom-
mendation, while acknowledging that they may still be valid
in high-risk scenarios.
Some members of the Work Group felt the available
evidence does not conclusively demonstrate that calcium-free
agents are superior to calcium-based agents. In addition, none
of the studies provided sufﬁcient dose-threshold information
about calcium exposure, nor did they give information on the
safety of moderately dosed calcium-containing binders in
combination therapies. Finally, because KDIGO guidelines are
intended for a global audience and calcium-free agents are
not available or affordable in all jurisdictions, recommending
against the use of calcium-based binders would imply that no
treatment is preferable to using calcium-based agents. Despite
the understandable clinical desire to have numeric targets and
limits, the Work Group could not make an explicit recom-
mendation about a maximum dose of calcium-based binders,
preferring to leave this to the judgment of individual physi-
cians while acknowledging the potential existence of a safe
upper limit of calcium dose.
Data are lacking on adverse effects of excess exposure to
calcium through diet, medications, or dialysate in children.
The Work Group concluded that there was insufﬁcient
evidence to change this recommendation in children, who
may be uniquely vulnerable to calcium restriction.
Dietary phosphate. There was no general controversy
regarding the 2009 KDIGO CKD-MBD Guideline1 recom-
mendation on dietary phosphate restriction to lower elevated
phosphate levels. However, the Work Group acknowledged
that the wording of the original statement was vague, espe-
cially with regard to new evidence on different phosphate and
phosphoprotein sources. Within the 2017 Update,3
predeﬁned criteria on study duration and cohort size pro-
hibited inclusion of some study reports for full evidence re-
view. Nevertheless, the Work Group felt that some of these
reports raised safety issues that require further discussion.
There are 3 major sources of phosphates in the diet: (i)
natural phosphates contained in raw or unprocessed foods,
(ii) phosphates added to foods during processing, and (iii)
phosphates in dietary supplements and medications. TheKidney International (2017) 92, 26–36amount of phosphorus contributed by food intake is
increasing with current processing practices that utilize
phosphorus-containing ingredients. However, aggressive di-
etary phosphate restriction is difﬁcult because it has the po-
tential to compromise adequate intake of other nutrients,
especially protein. Another consideration for modiﬁcation of
dietary phosphate and control of serum phosphate is the
“bioavailability” of phosphorus in different foods based on
the form: organic versus inorganic sources of phosphate.
Animal- and plant-based foods contain the organic form of
phosphate; food additives contain inorganic phosphate.
Approximately 40% to 60% of animal-based phosphate is
absorbed, while plant-based phosphate, mostly associated
with phytates, is less absorbable (generally 20%–50%). The
Work Group suggests including education about the best food
choices as they relate to absorbable phosphate. Additionally,
patients should be guided toward fresh and homemade foods,
rather than processed foods, to avoid additives.
Studies reviewed by the Work Group showed that various
types of nutrition education have had mixed results for
controlling serum phosphate. Considering all aspects of dietary
phosphate management, the Work Group decided not to
change the principal recommendation on phosphate
restriction. Instead, the Work Group added a qualiﬁer state-
ment suggesting that phosphate sources should be better sub-
stantiated and patient education should focus on best choices.
Maintaining serum calcium
As is the case for phosphate, novel epidemiological evidence
linking higher calcium concentrations to increased mortality
in adults with CKD has accumulated since the publication of
the 2009 KDIGO CKD-MBD Guideline.1 Additionally, new
studies have associated higher concentrations of serum cal-
cium with nonfatal cardiovascular events.
Because mild and asymptomatic hypocalcemia may well be
harmless, especially in the presence of calcimimetic therapy,
the Work Group emphasized an individualized approach to
the treatment of hypocalcemia, rather than recommending the
correction of hypocalcemia for all patients. However, signiﬁ-
cant or symptomatic hypocalcemia should still be addressed.
The 2009 Guideline1 considered that a dialysate calcium
concentration of 1.25 mmol/l (2.5 mEq/l) would yield neutral
calcium balance. Based on new evidence, the 2017Work Group
felt that this recommendation remains valid as written in 2009.
However, because additional studies of better quality are now
available, the evidence grade has been changed from 2D to 2C.
CHAPTER 4.2: TREATMENT OF ABNORMAL PTH LEVELS IN
CKD-MBD
Optimal PTH levels
Secondary hyperparathyroidism (SHPT) is characterized by a
complex pathogenesis driven by several factors, including
vitamin D deﬁciency, increasing ﬁbroblast growth factor 23
levels, hypocalcemia, and hyperphosphatemia, which can lead
to signiﬁcant abnormalities in bone mineralization and
turnover.31
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addressing modiﬁable risk factors for all patients with a PTH
level above the upper limit of normal for the assay used. Un-
fortunately, there is still an absence of RCTs that deﬁne an
optimal PTH level for patients with CKD G3a to G5. The 2017
Update Work Group felt that modest increases in PTH may
represent an appropriate adaptive response to declining kidney
function, due to phosphaturic effects and increasing bone
resistance to PTH. Therefore, the Update Work Group revised
the 2009 Guideline recommendation to reﬂect the fact that
treatment should not be based on a single elevated PTH value.
Further, the Work Group recognized an additional modi-
ﬁable risk factor: high phosphate intake. Increasingly, studies
have shown that excess phosphate intake does not always
result in hyperphosphatemia (especially in early CKD), and
that high phosphate intake may promote SHPT. Although
dietary phosphate intake is modiﬁable, the Work Group also
acknowledged that better methods for assessment of dietary
phosphate intake and balance are required.
Calcitriol and vitamin D analogs
Nondialysis patients. Prevention and treatment of SHPT is
important because imbalances in mineral metabolism are
associated with CKD-MBD, and higher PTH levels are asso-
ciated with increased morbidity and mortality in CKD pa-
tients. For many decades, calcitriol and other vitamin D
analogs have been the primary therapeutic option for treating
SHPT in individuals with CKD. The 2009 KDIGO CKD-
MBD Guideline1 summarized multiple studies demon-
strating that administration of calcitriol or vitamin D analogs
(such as paricalcitol, doxercalciferol, and alfacalcidol) resulted
in suppression of PTH levels. However, there was a notable
lack of trials demonstrating improvements in patient-
centered outcomes.
Additional RCTs of calcitriol or vitamin D analog therapy
have been published since the 2009 Guideline.1 Two of
these—the PRIMO and OPERA trials—demonstrated a
signiﬁcantly increased risk of hypercalcemia in patients
treated with paricalcitol compared with placebo, in the
absence of beneﬁcial effects on surrogate cardiac endpoints.
These results, combined with the opinion that moderate PTH
elevations may represent an appropriate adaptive response,
led the 2017 Update Work Group to conclude that the risk-
beneﬁt ratio of treating moderate PTH elevations was no
longer favorable. Therefore, the Update Work Group rec-
ommended that the use of calcitriol or vitamin D analogs
should be reserved only for severe and progressive SHPT.
Accordingly, the present Guideline3 no longer recommends
routine use of calcitriol or its analogs in CKD G3a to G5. This
change did not reach uniform consensus among the Work
Groupmembers. It should be noted that the participants in the
PRIMO and OPERA trials only had moderately increased PTH
levels; thus, therapy with calcitriol and vitamin D analogs may
be considered in those with progressive and severe SHPT.
No RCTs were identiﬁed that demonstrated the beneﬁcial
effects of calcitriol or vitamin D analogs on patient-level32outcomes, such as cardiac events or mortality, and the
optimal level of PTH in CKD G3a to G5 is not known.
Further, therapy with these agents may have additional
harmful effects related to increases in serum phosphate and
ﬁbroblast growth factor 23 levels. Therefore, the Work Group
concluded that—if initiated for severe and progressive
SHPT—calcitriol or vitamin D analogs should be started with
low doses, independent of the initial PTH concentration, and
then titrated based on the PTH response. Hypercalcemia
should be avoided.
Dialysis patients. New data prompted the 2017 Update
Work Group to reappraise the use of PTH-lowering therapies
in patients with CKD G5D. A couple new trials evaluated
treatment with cinacalcet versus placebo and 1 new trial
evaluated calcitriol versus a vitamin D analog. There are still
no new trials of calcitriol or vitamin D analogs that
demonstrated clear beneﬁts in patient-level outcomes.
The Update Work Group discussed the EVOLVE trial at
length. Members were divided as to whether the EVOLVE
data were sufﬁcient to recommend cinacalcet as a ﬁrst-line
option for all patients with SHPT and CKD G5D who
require PTH-lowering therapy.
One opinion is that the primary end point of the EVOLVE
study was negative. The alternative opinion is that secondary
analyses found effects on patient-level endpoints, while there
are no positive data on mortality or patient-centered end
points from trials with calcitriol or other vitamin D analogs.
Given the lack of consensus among the Work Group,
coupled with the higher acquisition cost of cinacalcet, the
2009 recommendation for patients with CKD G5D was
modiﬁed to list all acceptable treatment options in alpha-
betical order. The individual choice should continue to be
guided by considerations about concomitant therapies and
the patient’s calcium and phosphate levels. In addition, the
choice of dialysate calcium concentrations will impact serum
PTH levels. Finally, it should be pointed out that para-
thyroidectomy remains a valid treatment option, especially
when PTH-lowering therapies fail, as advocated in Recom-
mendation 4.2.5 from the 2009 KDIGO CKD-MBD
Guideline.1
CHAPTER 4.3: TREATMENT OF BONE WITH
BISPHOSPHONATES, OTHER OSTEOPOROSIS MEDICATIONS,
AND GROWTH HORMONE
The current Recommendation 3.2.2 addresses the indications
for a bone biopsy prior to antiresorptive and other osteopo-
rosis therapies. Therefore, the original Recommendation 4.3.4
from the 2009 KDIGO CKD-MBD Guideline1 was removed
and Recommendation 4.3.3 was extended from CKD G3a
through G3b to CKD G3a through G5D. Nevertheless, when
such treatment choices are considered, their speciﬁc side
effects must also be taken into account. For example, anti-
resorptives will exacerbate low bone turnover, and denosu-
mab may induce signiﬁcant hypocalcemia. The risk of
administering antiresorptives must be weighed against the
accuracy of the diagnosis of the underlying bone phenotype.Kidney International (2017) 92, 26–36
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TRANSPLANT BONE DISEASE
Assessment
The 2009 KDIGO CKD-MBD Guideline1 recommended
BMD testing in the ﬁrst 3 months following transplantation
in patients with an eGFR greater than 30 ml/min/1.73 m2 if
they receive corticosteroids or have risk factors for osteopo-
rosis. However, it was recommended that DXA BMD not be
performed in those with CKD G4T to G5T.
As detailed in the 2017 Recommendation 3.2.1,3 there is
growing evidence that DXA BMD predicts fractures across the
spectrum of CKD severity, including 4 prospective cohort
studies in patients with CKD G3a to G5D. There are limited
data suggesting that these ﬁndings extend to transplant re-
cipients. Therefore, the current Guideline3 recommends
BMD testing in transplant recipients, as in those with CKD
G3a to G5D, if the results will impact treatment decisions.
Treatment
The current Recommendation 3.2.2 now addresses the in-
dications for a bone biopsy prior to antiresorptive and other
osteoporosis therapies. Therefore, the 2009 Recommendation
5.6 concerning bone biopsies in transplant recipients has been
modiﬁed.SUMMARY OF KDIGO CKD-MBD RECOMMENDATIONS
UPDATED RECOMMENDATIONS ARE DENOTED IN BOXESCHAPTER 3.1: DIAGNOSIS OF CKD-MBD: BIOCHEMICAL
ABNORMALITIES3.1
3.1
3.2.1: In patients with CKD G3a–G5D with evidence
of CKD-MBD and/or risk factors for osteo-
porosis, we suggest BMD testing to assess
fracture risk if results will impact treatment
decisions (2B).
3.2.2: In patients with CKD G3a–G5D, it is reason-
able to perform a bone biopsy if knowledge of
the type of renal osteodystrophy will impact
treatment decisions (Not Graded).
Kidney I.1: We recommend monitoring serum levels of
calcium, phosphate, PTH, and alkaline phos-
phatase activity beginning in CKD G3a (1C).
In children, we suggest such monitoring begin-
ning in CKD G2 (2D).
.2: In patients with CKD G3a–G5D, it is reasonable
to base the frequency of monitoring serum cal-
cium, phosphate, and PTH on the presence and
magnitude of abnormalities, and the rate of
progression of CKD (Not Graded).
Reasonable monitoring intervals would be:3.2
3.2 In CKD G3a–G3b: for serum calcium and
phosphate, every 6–12 months; and for PTH,
based on baseline level and CKD progression.
 In CKD G4: for serum calcium and phosphate,
every 3–6 months; and for PTH, every 6–12
months.
 In CKD G5, including G5D: for serum calcium
and phosphate, every 1–3 months; and for
PTH, every 3–6 months.
 In CKD G4–G5D: for alkaline phosphatase ac-
tivity, every 12 months, or more frequently in
the presence of elevated PTH (see Chapter 3.2).nternational (2017) 92, 26–36In CKD patients receiving treatments for CKD-
MBD, or in whom biochemical abnormalities are
identiﬁed, it is reasonable to increase the frequency
of measurements to monitor for trends and treat-
ment efﬁcacy and side effects (Not Graded).
.3: In patients with CKD G3a–G5D, we suggest that
25(OH)D (calcidiol) levels might be measured,
and repeated testing determined by baseline
values and therapeutic interventions (2C).
We suggest that vitamin D deﬁciency and insuf-
ﬁciency be corrected using treatment strategies
recommended for the general population (2C).
.4: In patients with CKD G3a–G5D, we recommend
that therapeutic decisions be based on trends
rather than on a single laboratory value,
taking into account all available CKD-MBD
assessments (1C).
.5: In patients with CKD G3a–G5D, we suggest that
individual values of serum calcium and phosphate,
evaluated together, be used to guide clinical prac-
tice rather than the mathematical construct of
calcium-phosphate product (Ca 3 P) (2D).
.6: In reports of laboratory tests for patients with
CKD G3a–G5D, we recommend that clinical
laboratories inform clinicians of the actual assay
method in use and report any change in methods,
sample source (plasma or serum), and handling
speciﬁcations to facilitate the appropriate inter-
pretation of biochemistry data (1B).CHAPTER 3.2: DIAGNOSIS OF CKD-MBD: BONE.3: In patients with CKD G3a–G5D, we suggest that
measurements of serum PTH or bone-speciﬁc
alkaline phosphatase can be used to evaluate
bone disease because markedly high or low values
predict underlying bone turnover (2B).
.4: In patients with CKD G3a–G5D, we suggest not
routinely measuring bone-derived turnover
markers of collagen synthesis (such as procolla-
gen type I C-terminal propeptide) and break-
down (such as type I collagen cross-linked33
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34telopeptide, cross-laps, pyridinoline, or deoxy-
pyridinoline) (2C).
.5: We recommend that infants with CKD G2–G5D
have their length measured at least quarterly,
while children with CKD G2–G5D should be
assessed for linear growth at least annually (1B).4.1.8: In patients with CKD G3a–G5D, we suggest
limiting dietary phosphate intake in the
treatment of hyperphosphatemia alone orCHAPTER 3.3: DIAGNOSIS OF CKD-MBD: VASCULAR
CALCIFICATION4.1
in combination with other treatments (2D).
It is reasonable to consider phosphate
source (e.g., animal, vegetable, additives)
in making dietary recommendations (Not
Graded)..1: In patients with CKD G3a–G5D, we suggest that a
lateral abdominal radiograph can be used to
detect the presence or absence of vascular calci-
ﬁcation, and an echocardiogram can be used to
detect the presence or absence of valvular calci-
ﬁcation, as reasonable alternatives to computed
tomography–based imaging (2C).
.2: We suggest that patients with CKD G3a–G5D
with known vascular or valvular calciﬁcation be
considered at highest cardiovascular risk (2A).
It is reasonable to use this information to guide
the management of CKD-MBD (Not Graded).4.2.1: In patients with CKD G3a–G5 not on dialysis,
the optimal PTH level is not known. However,
we suggest that patients with levels of intactCHAPTER 4.1: TREATMENT OF CKD-MBD TARGETED AT
LOWERING HIGH SERUM PHOSPHATE AND MAINTAINING
SERUM CALCIUM4.2
4.2
.1: In patients with CKD G3a–G5D, treatments of
CKD-MBD should be based on serial assess-
ments of phosphate, calcium, and PTH levels,
considered together (Not Graded).
.2: In patients with CKD G3a–G5D, we suggest
lowering elevated phosphate levels toward the
normal range (2C).
.3: In adult patients with CKD G3a–G5D, we
suggest avoiding hypercalcemia (2C). In chil-
dren with CKD G3a–G5D, we suggest main-
taining serum calcium in the age-appropriate
normal range (2C).
.4: In patients with CKD G5D, we suggest using a
dialysate calcium concentration between 1.25
and 1.50 mmol/l (2.5 and 3.0 mEq/l) (2C).
.5: In patients with CKD G3a–G5D, decisions
about phosphate-lowering treatment should be
based on progressively or persistently elevated
serum phosphate (Not Graded).
.6: In adult patients with CKD G3a–G5D receiving
phosphate-lowering treatment, we suggest
restricting the dose of calcium-based phos-
phate binders (2B). In children with CKD
G3a–G5D, it is reasonable to base the choice of
phosphate-lowering treatment on serum cal-
cium levels (Not Graded)..7: In patients with CKD G3a–G5D, we recommend
avoiding the long-termuseof aluminum-containing
phosphate binders, and in patients with CKD G5D,
avoiding dialysate aluminum contamination to
prevent aluminum intoxication (1C)..9: In patients with CKD G5D, we suggest increasing
dialytic phosphate removal in the treatment of
persistent hyperphosphatemia (2C).CHAPTER 4.2: TREATMENT OF ABNORMAL PTH LEVELS IN
CKD-MBDPTH progressively rising or persistently
above the upper normal limit for the assay be
evaluated for modiﬁable factors, including
hyperphosphatemia, hypocalcemia, high
phosphate intake, and vitamin D deﬁciency
(2C).
.2: In adult patients with CKD G3a–G5 not on
dialysis, we suggest calcitriol and vitamin D
analogs not be routinely used (2C). It is
reasonable to reserve the use of calcitriol and
vitamin D analogs for patients with CKD G4–
G5 with severe and progressive hyperpara-
thyroidism (Not Graded).
In children, calcitriol and vitamin D analogs
may be considered to maintain serum calcium
levels in the age-appropriate normal range
(Not Graded)..3: In patients with CKD G5D, we suggest main-
taining intact PTH levels in the range of
approximately 2 to 9 times the upper normal
limit for the assay (2C).
We suggest that marked changes in PTH
levels in either direction within this range
prompt an initiation or change in therapy to
avoid progression to levels outside of this
range (2C).Kidney International (2017) 92, 26–36
4.2.4: In patients with CKD G5D requiring PTH-
lowering therapy, we suggest calcimimetics,
calcitriol, or vitamin D analogs, or a combina-
tion of calcimimetics with calcitriol or vitamin
D analogs (2B).
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Kidney Iperparathyroidism who fail to respond to medical
or pharmacological therapy, we suggest para-
thyroidectomy (2B).CHAPTER 4.3: TREATMENT OF BONE WITH
BISPHOSPHONATES, OTHER OSTEOPOROSIS MEDICATIONS,
AND GROWTH HORMONE5.3.1: In patients with CKD G1–G2 with osteoporosis
and/or high risk of fracture, as identiﬁed by
World Health Organization criteria, we recom-
mend management as for the general population
(1A).
.2: In patients with CKD G3a–G3b with PTH in the
normal range and osteoporosis and/or high risk of
fracture, as identiﬁed by World Health Organi-
zation criteria, we suggest treatment as for the
general population (2B).5.4
5.5: In patients with CKD G1T–G5T with risk factors
for osteoporosis, we suggest that BMD testing be
used to assess fracture risk if results will alter
therapy (2C).
5.6: In patients in the ﬁrst 12 months after kidney
transplant with an estimated glomerular ﬁltra-
tion rate greater than approximately 30 ml/min/
1.73 m2 and low BMD, we suggest that treatment
with vitamin D, calcitriol/alfacalcidol, and/or
antiresorptive agents be considered (2D).
.3: In patients with CKD G3a–G5D with
biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest
that treatment choices take into account the
magnitude and reversibility of the biochem-
ical abnormalities and the progression of
CKD, with consideration of a bone biopsy
(2D)..4: In children and adolescents with CKD G2–G5D
and related height deﬁcits, we recommend treat-
ment with recombinant human growth hormone
when additional growth is desired, after ﬁrst
addressing malnutrition and biochemical abnor-
malities of CKD-MBD (1A). We suggest that treatment choices be inﬂu-
enced by the presence of CKD-MBD, asCHAPTER 5: EVALUATION AND TREATMENT OF KIDNEY
TRANSPLANT BONE DISEASEindicated by abnormal levels of calcium,
phosphate, PTH, alkaline phosphatases, and
25(OH)D (2C).
 It is reasonable to consider a bone biopsy to
guide treatment (Not Graded).
There are insufﬁcient data to guide treatment
after the ﬁrst 12 months.: In patients in the immediate post–kidney trans-
plant period, we recommend measuring serum
calcium and phosphate at least weekly, until
stable (1B).
: In patients after the immediate post–kidney trans-
plant period, it is reasonable to base the frequency
of monitoring serum calcium, phosphate, and
PTH on the presence and magnitude ofnternational (2017) 92, 26–36abnormalities, and the rate of progression of CKD
(Not Graded).
Reasonable monitoring intervals would be: In CKD G1T–G3bT, for serum calcium and
phosphate, every 6–12 months; and for PTH,
once, with subsequent intervals depending on
baseline level and CKD progression.
 In CKD G4T, for serum calcium and phos-
phate, every 3–6 months; and for PTH, every
6–12 months.
 In CKD G5T, for serum calcium and phos-
phate, every 1–3 months; and for PTH, every
3–6 months.
 In CKD G3aT–G5T, measurement of alkaline
phosphatases annually, or more frequently in
the presence of elevated PTH (see Chapter 3.2).In CKD patients receiving treatments for CKD-
MBD, or in whom biochemical abnormalities are
identiﬁed, it is reasonable to increase the frequency
of measurements to monitor for efﬁcacy and side
effects (Not Graded).
It is reasonable to manage these abnormalities as for
patients with CKD G3a–G5 (see Chapters 4.1 and
4.2) (Not Graded).
: In patients with CKD G1T–G5T, we suggest that
25(OH)D (calcidiol) levels might be measured, and
repeated testing determined by baseline values and
interventions (2C).
: In patients with CKD G1T–G5T, we suggest that
vitamin D deﬁciency and insufﬁciency be corrected
using treatment strategies recommended for the
general population (2C).35
gu ide l i ne summary M Ketteler et al.: Summary of 2017 KDIGO CKD-MBD Guideline Update5.7: In patients with CKD G4T–G5T with known low36BMD, we suggest management as for patients with
CKD G4–G5 not on dialysis, as detailed in Chapters
4.1 and 4.2 (2C).DISCLOSURE
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